Research Progress of Dipeptidyl Peptidase 4 and Its Inhibitors in the Prevention and Treatment of Coronavirus Disease 2019
陈志会1,2,, 杨艳3, 凃玲1, 徐西振2
华中科技大学同济医学院附属同济医院1.综合医疗科
2.心血管内科
3.内分泌科,武汉 430030
CHEN Zhihui1,2,, YANG Yan3, TU Ling1, XU Xizhen2
1.Department of Geriatric Medicine
2.Division of Cardiology and Department of Internal Medicine
3.Division of Endocrinology and Department of Internal Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China
The pandemic of coronavirus disease 2019 (COVID-19) poses a huge threat to the world health,however,no clinical proven effective methods of treatment of COVID-19 were currently available.Recent study indicated that dipeptidyl peptidase 4 (DPP4) may be a potential receptor for the SARS-CoV-2,however,whether DPP4 directly participated in the adhesion or infection of SARS-CoV-2 to the target cells,and whether inhibition or modulation of DPP4 activity or expression could prevent the progression of COVID-19 still remain unclear.Previous studies revealed the anti-inflammatory and anti-fibrotic effects of DPP4 inhibitors.Thus,it is speculated that DPP4 inhibitors may play a protective role in inhibiting inflammatory response and pulmonary fibrosis in patients with COVID-19,but it still needs to be further confirmed.
CHENN,ZHOUM,DONGX,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J].Lancet,2020,395(10223):507-513.
ZHOUF,YUT,DUR,et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan,China:a retrospective cohort study[J].Lancet,2020,395(10229):1054-1062.
REMUZZIA,REMUZZIG.COVID-19 and Italy:what next?[J].Lancet,2020,395(10231):1225-1228.
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already taken on pandemic proportions, affecting over 100 countries in a matter of weeks. A global response to prepare health systems worldwide is imperative. Although containment measures in China have reduced new cases by more than 90%, this reduction is not the case elsewhere, and Italy has been particularly affected. There is now grave concern regarding the Italian national health system's capacity to effectively respond to the needs of patients who are infected and require intensive care for SARS-CoV-2 pneumonia. The percentage of patients in intensive care reported daily in Italy between March 1 and March 11, 2020, has consistently been between 9% and 11% of patients who are actively infected. The number of patients infected since Feb 21 in Italy closely follows an exponential trend. If this trend continues for 1 more week, there will be 30 000 infected patients. Intensive care units will then be at maximum capacity; up to 4000 hospital beds will be needed by mid-April, 2020. Our analysis might help political leaders and health authorities to allocate enough resources, including personnel, beds, and intensive care facilities, to manage the situation in the next few days and weeks. If the Italian outbreak follows a similar trend as in Hubei province, China, the number of newly infected patients could start to decrease within 3-4 days, departing from the exponential trend. However, this cannot currently be predicted because of differences between social distancing measures and the capacity to quickly build dedicated facilities in China.
ROTHAN HA,BYRAREDDY SN.The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak[J].J Autoimmun,2020,109:102433.
Coronavirus disease (COVID-19) is caused by SARS-COV2 and represents the causative agent of a potentially fatal disease that is of great global public health concern. Based on the large number of infected people that were exposed to the wet animal market in Wuhan City, China, it is suggested that this is likely the zoonotic origin of COVID-19. Person-to-person transmission of COVID-19 infection led to the isolation of patients that were subsequently administered a variety of treatments. Extensive measures to reduce person-to-person transmission of COVID-19 have been implemented to control the current outbreak. Special attention and efforts to protect or reduce transmission should be applied in susceptible populations including children, health care providers, and elderly people. In this review, we highlights the symptoms, epidemiology, transmission, pathogenesis, phylogenetic analysis and future directions to control the spread of this fatal disease.
RAJ VS,MOUH,SMITS SL,et al.Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC[J].Nature,2013,495(7440):251-254.
[本文引用:2]
[9]
KULCSARul KA,COLEMAN CM,BECK SE,et al.Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection[J].JCI Insight,2019.DOI:10.1172/jci.insight.131774.
[本文引用:1]
[10]
LIK,WOHLFORD-LENANEC L,CHANNAPPANAVARR,et al.Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice[J].Proc Natl Acad Sci U S A,2017.DOI:10.1073/pnas.1619109114.
[本文引用:1]
[11]
VANKADARIN,WILCE JA.Emerging Wuhan (COVID-19) coronavirus:glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26[J].Emerg Microbes Infect,2020,9(1):601-604.
The recent outbreak of pneumonia-causing COVID-19 in China is an urgent global public health issue with an increase in mortality and morbidity. Here we report our modelled homo-trimer structure of COVID-19 spike glycoprotein in both closed (ligand-free) and open (ligand-bound) conformation, which is involved in host cell adhesion. We also predict the unique N- and O-linked glycosylation sites of spike glycoprotein that distinguish it from the SARS and underlines shielding and camouflage of COVID-19 from the host the defence system. Furthermore, our study also highlights the key finding that the S1 domain of COVID-19 spike glycoprotein potentially interacts with the human CD26, a key immunoregulatory factor for hijacking and virulence. These findings accentuate the unique features of COVID-19 and assist in the development of new therapeutics.
TAIW,HEL,ZHANGX,et al.Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus:implication for development of RBD protein as a viral attachment inhibitor and vaccine[J].Cell Mol Immunol,2020.DOI:10.1038/s41423-020-0400-4.
[本文引用:1]
[13]
ZHENGT,GAOY,BASKOTAA,et al.Increased plasma DPP4 activity is predictive of prediabetes and type 2 diabetes onset in Chinese over a four-year period:result from the China National Diabetes and Metabolic Disorders Study[J].J Clin Endocrinol Metab,2014.DOI:10.1210/jc.2014-1480.
BARCHETTAI,CICCARELLIG,BARONEE,et al.Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus[J].Nutr Metab Cardiovasc Dis,2019,29(10):1087-1094.
[本文引用:1]
[15]
BARCHETTAI,CAVALLO MG,BARONI MG.COVID-19 and diabetes:is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications[J].Diabetes Res Clin Pract,2020.DOI:10.1016/j.diabres.2020.108165.
INN KS,KIMY,AIGERIMA,et al.Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus[J].Virology,2018.DOI:10.1016/j.virol.2018.03.015.
Increasing evidences indicate that high-risk HPV variants are heterogeneous in carcinogenicity and ethnic dispersion. In this work, we identified genetic signatures for convenient determination of lineage/sublineage of HPV16, 18, 52 and 58 variants. Using publicly available genomes, we found that E2 of HPV16, L2 of HPV18, L1 and LCR of HPV52, and L2, LCR and E1 of HPV58 contain the proper genetic signature for lineage/sublineage classification. Sets of hierarchical signature nucleotide positions were further confirmed for high accuracy (>95%) by classifying HPV genomes obtained from Chinese females, which included 117 HPV16 variants, 48 HPV18 variants, 117 HPV52 variants and 89 HPV58 variants. The circulation of HPV variants posing higher cancer risk in Eastern China, such as HPV16 A4 and HPV58 A3, calls for continuous surveillance in this region. The marker genes and signature nucleotide positions may facilitate cost-effective diagnostic detections of HPV variants in clinical settings.
HAVERKAMP AK,LEHMBECKERA,SPITZBARTHI,et al.Experimental infection of dromedaries with Middle East respiratory syndrome coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4[J].Sci Rep,2018.DOI:10.1038/s41598-018-28109-2.
[本文引用:1]
[18]
VADUGANATHANM,VARDENYO,MICHELT,et al.Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19[J].N Engl J Med,2020,382(17):1653-1659.
[本文引用:1]
[19]
BERGER JP,SINHAROYR,POCAIA,et al.A compa-rative study of the binding properties,dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin,linagliptin,saxagliptin,sitagliptin and vildagliptin in mice[J].Endocrinol Diabetes Metab,2017.DOI:10.1002/edm2.2.eCollection 2018 Jan.
[本文引用:1]
[20]
ENGELM,HOFFMANNT,WAGNERL,et al.The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism[J].Proc Natl Acad Sci U S A,2003,100(9):5063-5068.
[本文引用:1]
[21]
GORRELL MD,GYSBERSV,MCCAUGHAN GW.CD26:a multifunctional integral membrane and secreted protein of activated lymphocytes[J].Scand J Immunol,2001,54(3):249-264.
OHNUMAK,HAAGMANS BL,HATANOaR,et al.Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody[J].J Virol,2013,87(24):13892-13899.
PITOCCOD,TARTAGLIONEL,VITIL,et al.SARS-CoV-2 and DPP4 inhibition:Is it time to pray for Janus Bifrons?[J].Diabetes Res Clin Pract,2020.DOI:10.1016/j.diabres.2020.108162.
STROLLOR,POZZILLIP.DPP4 inhibition:preventing SARS-CoV-2 infection and/or progression of COVID‐19?[J].Diabetes Metab Res Rev,2020.DOI:10.1002/dmrr.3330.
Diabetic retinopathy (DR) is one of the leading causes of blindness worldwide, and the limited availability of qualified ophthalmologists restricts its early diagnosis. For the past few years, artificial intelligence technology has developed rapidly and has been applied in DR screening. The upcoming technology provides support on DR screening and improves the identification of DR lesions with a high sensitivity and specificity. This review aims to summarize the progress on automatic detection and classification models for the diagnosis of DR.
STEINBRECHERA,REINHOLDD,QUIGLEYL,et al.Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo[J].J Immunol,2001,166(3):2041-2048.
CD26 or dipeptidyl peptidase IV (DP IV) is expressed on various cell types, including T cells. Although T cells can receive activating signals via CD26, the physiological role of CD26/DP IV is largely unknown. We used the reversible DP IV inhibitor Lys[Z(NO(2))]-pyrrolidide (I40) to dissect the role of DP IV in experimental autoimmune encephalomyelitis (EAE) and to explore the therapeutic potential of DP IV inhibition for autoimmunity. I40 administration in vivo decreased and delayed clinical and neuropathological signs of adoptive transfer EAE. I40 blocked DP IV activity in vivo and increased the secretion of the immunosuppressive cytokine TGF-beta1 in spinal cord tissue and plasma during acute EAE. In vitro, while suppressing autoreactive T cell proliferation and TNF-alpha production, I40 consistently up-regulated TGF-beta1 secretion. A neutralizing anti-TGF-beta1 Ab blocked the inhibitory effect of I40 on T cell proliferation to myelin Ag. DP IV inhibition in vivo was not generally immunosuppressive, neither eliminating encephalitogenic T cells nor inhibiting T cell priming. These data suggest that DP IV inhibition represents a novel and specific therapeutic approach protecting from autoimmune disease by a mechanism that includes an active TGF-beta1-mediated antiinflammatory effect at the site of pathology.
SEONG JM,YEEJ,GWAK HS.Dipeptidyl peptidase‐4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus:a nationwide population‐based cohort study[J].Br J Clin Pharmacol,2019,85(8):1719-1727.
YANGW,CAIX,HANX,et al.DPP-4 inhibitors and risk of infections:a Meta-analysis of randomized controlled trials[J].Diabetes Metab Res Rev,2016,32(4):391-404.
SOAREA,GYOFI HA,MATEI AE,et al.Dipeptidylpep-tidase 4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in systemic sclerosis[J].Arthritis Rheumatol,2019,72(1):137-149.
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus:implication for development of RBD protein as a viral attachment inhibitor and vaccine
Increased plasma DPP4 activity is predictive of prediabetes and type 2 diabetes onset in Chinese over a four-year period:result from the China National Diabetes and Metabolic Disorders Study
Experimental infection of dromedaries with Middle East respiratory syndrome coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4
A compa-rative study of the binding properties,dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin,linagliptin,saxagliptin,sitagliptin and vildagliptin in mice
Dipeptidyl peptidase‐4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus:a nationwide population‐based cohort study
, 杨艳
